Efficacy and safety of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysis
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2018
Price : $35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Nov 2018 Status changed from recruiting to completed.
- 03 Dec 2017 Status changed from not yet recruiting to recruiting.
- 23 Nov 2017 New trial record